Other Clinical Trial - A Study of Pasireotide in People With Prolactinoma

Clinical Trial Summary

The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04106531` - Validation of a Quality of Life Metric "Prolac-10"
	Recruiting	`NCT04107480` - PRolaCT - Three Prolactinoma RCTs	Phase 4

See also

Status

Clinical Trial

Phase

Terminated

NCT04106531 - Validation of a Quality of Life Metric "Prolac-10"

Recruiting

NCT04107480 - PRolaCT - Three Prolactinoma RCTs

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06295952
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Eliza Geer, MD
Phone	646-608-3797
Email	geere@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	February 27, 2024
Completion date	February 2027

A Study of Pasireotide in People With Prolactinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms